Source: Annual Congress 2004 - COPD: insights from structure and function
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. E. Makarevich (Minsk, Belarus). Interaction of hemostasis (H) and immune response (IR) in COPD development. Eur Respir J 2004; 24: Suppl. 48, 832

Member's Comments

No comment yet.

Related content which might interest you: Influence of bacterial colonization (BC) on the level of systemic inflammatory markers (SIM) in COPD patients (pts) Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Viral infection (VI) and role of oxidative stress (OS) in asthma exacerbation Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004 Humoral immune response to recombinant and native mycobacterial antigens in different forms of pulmonary tuberculosis (TB) in adults (A) and children (C) Source: Eur Respir J 2004; 24: Suppl. 48, 32s Year: 2004 Relationship between salivary markers of oxidative stress (OS) and different levels of control of bronchial asthma (BA). Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Transforming growth factor beta (TGF-β) augments rhinovirus (RV) replication in primary bronchial epithelial cells (pbecs) through modulation of the innate immune response Source: Annual Congress 2009 - Viruses and respiratory infections: prevalence and mechanisms of infection Year: 2009 Time course relationships of Type 1 and 2 inflammatory and innate immune pathways during Human Rhinovirus (HRV) infection in subjects with asthma Source: International Congress 2018 – Asthma analysis Year: 2018 Host response (immune response) Source: Virtual Congress 2020 – Basic science Year: 2020 COPD: Acute exacerbation (AE) and hospitalization rate (HR) in patients with different serum surfactant protein D (SPD) level Source: Annual Congress 2012 - COPD exacerbation Year: 2012 Serum surfactant protein D (SPD) and response to the combined therapy in patients (pts) with stable COPD Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Reproducibility of resistance (R) and reactance (X) responses to bronchodilator (BD) measured by the impulse oscillation system (IOS) in patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 63s Year: 2005 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Pulmonary function test (PT) and physical fitness (F) in asthmatic children Source: Eur Respir J 2005; 26: Suppl. 49, 395s Year: 2005 Is the strength of the type-2 (T2) inflammatory biomarker signal important in determining the burden of disease in severe asthma (SA)? Source: Virtual Congress 2020 – Phenotypes of obstructive diseases Year: 2020 Increased METEORIN-LIKE (ML) expression promotes lung inflammation in asthma. Source: International Congress 2019 – Novel mechanisms elucidated by translational studies of asthma Year: 2019 Frequency of autoantibodies (autoAb) and circulating immune complexes (CI) occurrences in pulmonary sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Host response (airway/lung effects) Source: Virtual Congress 2020 – Basic science Year: 2020 Lymphoid follicles in (very) severe COPD: beneficial or harmful? Source: Eur Respir J 2009; 34: 219-230 Year: 2009 Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD) Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001